Company plans to initiate the Phase 1/2 clinical trial for ST-920 in 2019
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sangamo Therapeutics Inc , where a total of 21,510 contracts have traded so far, representing approximately 2.2 million underlying shares. That amounts to about 128.3% of SGMO's average daily trading volume over the past month of 1.7 million shares.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
-- Administration of SB-318 was generally well tolerated in all 3 subjects across 2 dosing cohorts, up to a dose of 5e13 vg/kg (2 patients)
- Liver biopsy analysis detected targeted integration of IDS transgene, providing preliminary molecular evidence of in vivo genome editing in humans
Let's take a look at the charts and indicators.
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.
Jim Cramer weighs in on Brinks, Sangamo Biosciences, Medtronic, Fiat Chrysler, GW Pharmaceuticals, EPR Properties.
The most recent short interest data was recently released for the 12/14/2018 settlement date, and Sangamo Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 11.12 "days to cover" versus the median component at 4.32. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
RICHMOND, Calif., Jan.
RICHMOND, Calif., Jan.
Investors in Sangamo Therapeutics Inc saw new options become available this week, for the August 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
RICHMOND, Calif. and VALBONNE, France, Dec.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time
RICHMOND, Calif., Nov.
RICHMOND, Calif., Nov.
The most recent short interest data was recently released for the 09/28/2018 settlement date, and Sangamo Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.54 "days to cover" versus the median component at 4.65. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy
RICHMOND, Calif., Sept.
Investors in Sangamo Therapeutics Inc saw new options begin trading this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
SSIEM presentation included early data from Cohorts 1 (low dose) and 2 (mid dose); enrollment of Cohort 3 (high dose, 5x the mid dose) was recently completed
Despite $5.1 billion deal for Costa, I'm not slurping any KO up.
You don't have to be Sigmund Freud to understand the psychology here.
I expect CRM to regain its footing quickly and challenge highs again soon.
